⚠ Evidence warning: Clinical trials or other evidence do not support the claims that valerian-lemon balm combinations work better than either herb alone and that they help people taper off prescription sleeping pills. This page keeps it as a report of what people, websites or other media say.
Lemon Balm for Sleep Quality
Lemon balm is most commonly used not as a primary sedative but as the calming partner in valerian-lemon balm combinations — valerian provides the sleep-onset push, lemon balm prevents the next-day grogginess and adds a layer of mucosal calming through its GABAergic effect. The two most-cited studies are the Cases 2011 open-label trial of a standardized lemon balm extract (600 mg/day) in 20 volunteers with mild-to-moderate anxiety and concurrent sleep disturbance, and the Müller and Klement 2006 open multicentre study of a valerian-plus-lemon-balm combination in 918 children under 12 with restlessness and dyssomnia. Neither had a placebo group; both reported improvements in sleep symptoms and no study-medication-related adverse effects, and a small 2024 placebo-controlled crossover trial reported better sleep scores with a lemon balm extract. This page walks through the mechanism (shared GABAergic action with valerian, plus contributions from citral and rosmarinic acid), the doses used in trials and in herbal practice for daytime and evening use, and how lemon balm-containing sleep products compare with plain valerian, melatonin and prescription Z-drugs.
Table of Contents
- Why Lemon Balm Matters for Sleep
- The Cases 2011 Lemon Balm Extract Trial
- A Placebo-Controlled Crossover Trial in 2024
- The Müller-Klement 2006 Pediatric Trial
- The Shared GABAergic Mechanism
- Dose Timing: Daytime Anxiolytic vs Evening Sleep Onset
- Lemon Balm Plus Valerian Combinations
- Lemon Balm Plus Chamomile and Passionflower
- Lemon Balm vs Melatonin
- Lemon Balm vs Zolpidem and the Z-Drugs
- Sleep Protocols Described by Phenotype
- Cautions and Drug Interactions
- Key Research Papers
- Connections
- Featured Videos
Why Lemon Balm Matters for Sleep
Insomnia is conventionally divided into three phenotypes: difficulty falling asleep (sleep-onset insomnia), difficulty staying asleep (sleep-maintenance insomnia), and early-morning awakening with inability to return to sleep. These phenotypes have different physiology and respond to different interventions. The largest of the three by population prevalence — sleep-onset insomnia, particularly in patients whose racing thoughts and physiological hyperarousal prevent the transition from wakefulness to sleep — is the type best served by lemon balm.
The physiological transition from awake to asleep requires a coordinated drop in sympathetic nervous system tone, a rise in parasympathetic activation, and an inhibitory shift in the prefrontal cortex that allows the default mode network and rumination circuits to quiet. Stress-driven insomnia is characterized by failure of this transition — sympathetic tone remains elevated, the prefrontal cortex stays engaged in problem-solving and worry, and the resulting hyperaroused state is incompatible with sleep onset.
Pharmacologic strategies for stress-driven sleep-onset insomnia divide into three broad categories:
- Direct gamma-aminobutyric acid-A agonists or modulators — benzodiazepines (lorazepam, temazepam), Z-drugs (zolpidem, eszopiclone, zaleplon). Highly effective for sleep onset but with dependence, tolerance, next-day cognitive impairment, and complex sleep behaviors
- Indirect GABAergic agents — valerian, lemon balm, kava, hops. Modulate GABAergic tone through diverse mechanisms (gamma-aminobutyric acid-T inhibition, allosteric receptor modulation, increased gamma-aminobutyric acid (GABA) release) with much milder effect but excellent safety
- Circadian agents — melatonin, ramelteon, agomelatine. Target the circadian phase rather than the gamma-aminobutyric acid system; most useful for circadian-rhythm sleep disturbance rather than primary insomnia
Lemon balm sits in the indirect GABAergic category, complementing rather than replacing valerian. Its sleep-supportive effect is real but modest in isolation; combined with valerian it is part of one of the best-studied non-prescription sleep formulations in European phytotherapy.
The anxiety side of that effect has been pooled across trials. A 2021 systematic review and meta-analysis of randomized trials (Ghazizadeh and colleagues) found that lemon balm improved anxiety scores (standardized mean difference −0.98) and depression scores (−0.47) compared with placebo, without serious side effects. The authors note that the trials were few, differed in method and gave widely varying results (high heterogeneity), so the findings are to be read with caution.
The Cases 2011 Lemon Balm Extract Trial
The most-cited lemon-balm-monotherapy sleep trial was published by Jonathan Cases and colleagues in 2011 (Mediterranean Journal of Nutrition and Metabolism). The study was a prospective, single-center, open-label pilot trial in 20 stressed volunteers (outpatients; 14 women and 6 men aged 18 to 70) with mild-to-moderate anxiety disorders and sleep disturbances, recruited through advertisements and from the outpatient Dietetics and Clinical Nutrition Unit of San Martino University Hospital in Genoa, Italy. The intervention was a standardized hydroalcoholic Melissa officinalis leaf extract, standardized to more than 7% rosmarinic acid and more than 15% hydroxycinnamic acid derivatives, given as 300 mg in the morning and 300 mg in the evening before sleep (600 mg/day) for 15 days. Four of the five authors worked for the extract's manufacturer, which also gave the study financial assistance.
Outcome measures at baseline and day 15 included:
- A 20-question interview inventory based on the Free Rating Scale for Anxiety (FRSA) — scoring anxiety manifestations and anxiety-associated symptoms
- Insomnia items from the Hamilton Rating Scale for Depression (HRSD) — scoring initial, middle and delayed insomnia
- Clinical Global Impression-Improvement scale (CGI-I) — the clinician's rating of overall improvement
After 15 days of treatment, the trial reported:
- Anxiety manifestations reduced by 18% and anxiety-associated symptoms by 15% (both p < 0.01)
- Insomnia reduced by 42% (p < 0.01)
- 19 of 20 participants (95%) responded to treatment; 14 of 20 (70%) reached full remission of anxiety, 17 of 20 (85%) of insomnia, and 14 of 20 (70%) of both
- No adverse effects were observed, and all volunteers completed the study
The trial has the standard limitations of an open-label pilot — no placebo control, small sample size, single proprietary extract, short duration — and the authors themselves write that the open-label design cannot rule out a placebo effect and that future studies must include a placebo arm.
A Placebo-Controlled Crossover Trial in 2024
A 2024 double-blind, placebo-controlled crossover study in Italy (Di Pierro and colleagues, Nutrients) tested a lemon balm extract bound to phospholipids (a “phytosome” form made to be absorbed better). Thirty adults took two 200 mg tablets of the extract or of a placebo every evening 30 minutes before bed for two weeks each, with a one-week break between the two periods. The study reported:
- Insomnia Severity Index — an average score of 6.8 with the extract versus 9.7 with placebo, 2.9 points lower (p = 0.003)
- Reported sleep quality — 87% of participants reported better sleep with the extract, against 30% with placebo
- Sleep stages (measured with a wrist device) — deep (slow-wave) sleep rose by about 15% and rapid-eye-movement (REM) sleep fell by about 10%
- Anxiety and physical activity — no significant change
The study was small and short, and its first author is scientific director of the company that sells the extract, with two other authors consultants to it.
The Müller-Klement 2006 Pediatric Trial
The largest study of a lemon-balm-containing sleep formulation in children was the open, uncontrolled multicentre study published by Sabine F. Müller and Susanna Klement in 2006 (Phytomedicine). It evaluated 918 children under 12 years of age with restlessness and nervous sleep difficulty ("dyssomnia"). The intervention was a fixed-dose combination product of 160 mg valerian extract plus 80 mg lemon balm extract per tablet, and the investigators dosed each child individually. The first author worked for the company that makes the product.
Parents and investigators scored:
- Severity of restlessness — physician 4-point scale, parent rating
- Severity of dyssomnia (sleep difficulty) — physician 4-point scale, parent rating
- Global treatment efficacy — physician and parent both
- Treatment tolerability — including documentation of any adverse events
Results:
- The core symptoms, dyssomnia and restlessness, fell from "moderate/severe" to "mild" or "absent" in most of the children
- 80.9% of the children with dyssomnia improved on that symptom, and 70.4% of those with restlessness improved clearly; the other listed symptoms improved by 37.8% on average
- Parents and investigators rated efficacy "very good" or "good" in 60.5% and 67.7% of cases, respectively
- Tolerability was judged "very good" or "good" in 96.7% of the children
- No study medication-related adverse events occurred
This study remains the principal evidence cited for valerian-lemon balm combination products for restlessness and sleep difficulty in children in European phytotherapy practice. It had no placebo or comparison group, which limits causal interpretation; its main contribution is tolerability data in a large group of children.
The Shared GABAergic Mechanism
The synergy between valerian and lemon balm in sleep formulations is mechanistically rational because both herbs act on the GABAergic system but at different points:
- Valerian (Valeriana officinalis) — multiple constituents act on the gamma-aminobutyric acid system. Valerenic acid binds allosterically to the gamma-aminobutyric acid-A receptor at the beta-3 subunit binding site, producing direct receptor modulation; the iridoid valepotriates also contribute. Valerian additionally inhibits gamma-aminobutyric acid reuptake into presynaptic terminals, raising synaptic gamma-aminobutyric acid concentration.
- Lemon balm (Melissa officinalis) — rosmarinic acid and possibly the volatile monoterpenes inhibit gamma-aminobutyric acid-transaminase, the catabolic enzyme that breaks down gamma-aminobutyric acid in the synapse. This raises standing gamma-aminobutyric acid concentration through a different mechanism than valerian's reuptake inhibition.
The combined effect is increased synaptic gamma-aminobutyric acid from two complementary mechanisms (reduced reuptake plus reduced catabolism), acting on a gamma-aminobutyric acid-A receptor whose response is enhanced by valerenic acid's allosteric modulation. This multi-point GABAergic stack is the proposed reason the combination would give a stronger and more reliable sleep-supportive effect than either herb alone.
The advantage of indirect GABAergic potentiation over direct benzodiazepine-style receptor agonism is selectivity. Benzodiazepines act on every gamma-aminobutyric acid-A receptor in the brain at once, producing sleep but also amnesia, ataxia, and the muscle relaxation that contributes to falls. Indirect potentiation through gamma-aminobutyric acid-T inhibition or reuptake inhibition raises GABAergic tone preferentially in synapses that were already firing, which preserves more of the physiological pattern of sleep and produces less of the global central nervous system (CNS) suppression that causes benzodiazepine side effects.
This is the pharmacological reason that valerian-lemon balm combinations rarely cause next-day grogginess at typical doses, while equivalent benzodiazepine doses commonly do.
Dose Timing: Daytime Anxiolytic vs Evening Sleep Onset
The same lemon balm extract is used as a daytime anxiolytic or as an evening sleep-onset aid, with different timing. The doses below are those used in the trials on this page or described in herbal practice:
- Daytime anxiolytic use — herbal practice describes 300 mg standardized extract two to three times daily (morning, mid-afternoon, optionally early evening), or 2-3 cups of mild tea spread across the day, aiming at steady low-grade calming without sedation.
- Evening sleep-onset use — herbal practice describes 600-900 mg standardized extract, or 1-2 strong cups of tea, 60-90 minutes before intended sleep. The stated rationale is to place peak plasma rosmarinic acid in the wake-to-sleep transition window. Practitioners pair it with sleep hygiene measures (dim lighting, no screens, cool bedroom).
- Combined daytime anxiety and insomnia — the Cases 2011 trial used 300 mg in the morning plus 300 mg in the evening before sleep, the morning dose aimed at daytime anxiety and the evening dose at sleep onset. The 2024 crossover trial used 400 mg of a phytosome extract 30 minutes before bed.
- Valerian combination in the evening — combination products supply 160-300 mg valerian extract plus 80-160 mg lemon balm extract, usually taken 30-60 minutes before bed; practitioners describe it as often more effective than either single herb at the same total dose. The Müller-Klement 2006 study used a fixed-dose combination of this type.
Onset of sleep-supportive effect from oral lemon balm is described as typically 45-90 minutes (somewhat slower than benzodiazepines or Z-drugs, which act within 15-30 minutes). For people used to fast-acting sleeping pills, the slower onset can feel like ineffectiveness; the herb is described as needing more lead time and as more useful for "winding down" before sleep than for fast sleep onset.
Lemon Balm Plus Valerian Combinations
The valerian-plus-lemon-balm combination is the canonical European phytotherapy sleep formulation. The product used in the Müller-Klement 2006 study provides 160 mg valerian extract and 80 mg lemon balm extract per tablet. The fixed-dose ratio reflects the relative anxiolytic and sleep-onset contributions of each herb — valerian carries most of the sleep-onset signal, lemon balm contributes the calming anxiolytic background.
Trial evidence for the combination specifically:
- Cerny & Schmid 1999 — a double-blind, placebo-controlled, multicentre study of the tolerability and efficacy of a valerian-lemon balm combination in healthy volunteers (Fitoterapia).
- Müller & Klement 2006 — the open, uncontrolled 918-child study discussed above.
- Several smaller European trials in postmenopausal women with menopause-related sleep disturbance, in alcohol detoxification-related insomnia, and in benzodiazepine-tapering sleep disturbance — all showing meaningful improvements with the combination.
In European phytotherapy practice the valerian-lemon balm combination is used as a non-prescription option for sleep-onset difficulty with anxiety. The regimen usually described is 1-2 tablets of a 160 mg valerian + 80 mg lemon balm fixed-dose product, 30-60 minutes before bed. Practitioners describe the effect as more reliable after 2-3 weeks of nightly use than from a single dose, with as-needed use also common.
Valerian itself, the main partner in these combinations, has weak trial support on its own. A 2007 systematic review of 37 studies (Taibi and colleagues, titled “A systematic review of valerian as a sleep aid: safe but not effective”) found that most controlled studies showed no significant difference between valerian and placebo, in healthy people or in people with insomnia; none of the most recent and most rigorous studies found a significant effect on sleep; and adverse events were rare.
See Valerian for the full valerian profile.
Lemon Balm Plus Chamomile and Passionflower
A broader European phytotherapy tradition combines lemon balm with chamomile, passionflower, and sometimes hops in multi-herb anxiolytic-sleep blends. The pharmacology rationale is the same multi-target GABAergic potentiation discussed above, with chamomile's apigenin contributing benzodiazepine-binding-site partial agonism, passionflower's flavonoids contributing additional gamma-aminobutyric acid-A modulation, and hops contributing methylbutenol-derived sedation.
Trial evidence for these broader combinations is sparser than for the valerian-lemon balm pairing, but the tradition is long-established and the combinations are well-tolerated. Common formats include:
- Tea blends ("calming tea", "bedtime tea", "sleepytime tea") combining 2-3 of lemon balm, chamomile, passionflower, hops, lavender, and oat straw
- Tincture blends in similar proportions, dispensed by Western herbalists
- Multi-herb capsule formulations
- "Nervine" combinations used in homeopathic and biochemic medicine traditions
The practical advantage of multi-herb formulations is broader-spectrum coverage of different sleep phenotypes — sleep-onset (valerian, hops), middle-of-the-night awakening (passionflower), sleep-maintenance (chamomile), and the underlying daytime anxiety that drives chronic insomnia (lemon balm). The disadvantage is reduced dose precision per ingredient and harder reproducibility.
See Chamomile and Passionflower.
Lemon Balm vs Melatonin
Melatonin is the most-used over-the-counter sleep aid in the United States, with annual sales exceeding 500 million USD. Mechanistically, melatonin is fundamentally different from lemon balm — it is the endogenous circadian signal of darkness, working through MT1 and MT2 receptors in the suprachiasmatic nucleus to advance or delay circadian phase, rather than through any GABAergic mechanism. Its primary value is for circadian-rhythm sleep disturbance (jet lag, shift work, delayed sleep-phase syndrome) rather than primary insomnia.
Compared to melatonin, lemon balm has:
- Different indication — lemon balm for stress-driven sleep onset; melatonin for circadian phase problems
- Different mechanism — GABAergic vs circadian receptor signaling. The two are sometimes combined by people with both stress-related sleep onset difficulty and a delayed circadian phase
- Better profile for daytime anxiety — lemon balm has documented anxiolytic effects useful through the day; melatonin has no significant anxiolytic effect
- Melatonin products and their labels — a 2017 analysis of 31 over-the-counter (OTC) melatonin supplements found melatonin content ranging from 83% below to 478% above the labeled amount; more than 71% were not within 10% of the label claim, and 8 products (26%) contained serotonin. No comparable analysis of lemon balm products is cited here, and US over-the-counter supplements in general vary in quality
- No documented circadian disruption from late dosing — melatonin taken at the wrong time of day can shift circadian phase undesirably; lemon balm timing is forgiving
Melatonin's research base lies mainly in circadian phase problems (jet lag east-bound, shift work, delayed sleep-phase syndrome); lemon balm and valerian-lemon balm combinations are used mainly for stress-driven sleep onset difficulty with anxiety. Some people use both, taken at different times for different reasons.
Lemon Balm vs Zolpidem and the Z-Drugs
The Z-drugs — zolpidem, eszopiclone, zaleplon — are the most-prescribed sleep medications in the United States. They are non-benzodiazepine gamma-aminobutyric acid-A agonists that selectively bind the alpha-1 subunit of the gamma-aminobutyric acid-A receptor, producing sleep onset within 15-30 minutes. They are effective for short-term insomnia management but carry well-documented risks: complex sleep behaviors (sleep-driving, sleep-eating, sleep-walking), anterograde amnesia, falls in elderly patients, dependence, and rebound insomnia on discontinuation.
Lemon balm-containing sleep formulations cannot match Z-drugs on speed of sleep onset or absolute efficacy in severe insomnia. They can, however, offer:
- No complex sleep behaviors — the Z-drug boxed warning about complex sleep behaviors (sleep-walking, sleep-driving, and other activities while not fully awake) does not apply to lemon balm or valerian
- No reported dependence or tolerance — no withdrawal or rebound has been reported in the short trials of lemon balm
- No anterograde amnesia — the memory blackouts that some Z-drug users experience are absent with lemon balm
- Better next-day cognitive function — Z-drugs commonly produce next-day grogginess and impaired driving performance; lemon balm does not
- Better safety in the elderly — the increased fall risk and confusion risk associated with Z-drugs in older patients is largely absent with lemon balm and valerian
- Used as a step-down aid — herbal practitioners use lemon balm combinations during gradual discontinuation of chronic Z-drug use, describing them as replacing part of the GABAergic effect with a milder alternative during the taper
The current U.S. Food and Drug Administration (FDA)-approved labels describe zolpidem and zaleplon for the short-term treatment of insomnia: zolpidem shortened the time to fall asleep for up to 35 days in controlled studies (trials of 4 to 5 weeks), and zaleplon for up to 30 days. The eszopiclone label lists the treatment of insomnia, with supporting trials of up to 6 months. All three labels carry a boxed warning about complex sleep behaviors and warn that withdrawal symptoms may occur with rapid dose reduction or stopping. In herbal practice, lemon balm-containing combinations are used for chronic mild-to-moderate sleep difficulty, by people who want to avoid prescription dependence, in older adults, in whom Z-drugs carry particular risks of falls and confusion, and during tapering off chronic Z-drug or benzodiazepine use.
Sleep Protocols Described by Phenotype
The trials above and herbal practice describe different approaches for different sleep problems:
- Stress-driven sleep-onset insomnia with daytime anxiety — the most common lemon balm use. The Cases 2011 trial gave 300 mg standardized extract in the morning and in the evening before sleep; in that open study 17 of 20 volunteers reached full remission of insomnia by day 15. Herbalists also describe a strong cup of lemon balm tea at bedtime.
- Sleep-onset insomnia without daytime anxiety — herbal practice describes a valerian-lemon balm combination 30-60 minutes before bed (160 mg valerian + 80 mg lemon balm; one or two tablets), without daytime doses.
- Sleep-maintenance insomnia (frequent night wakings) — lemon balm is described as less effective for this phenotype than for sleep onset; herbalists use passionflower as the main herb, with lemon balm as an evening calming adjunct. Sleep apnea, restless legs, gastroesophageal reflux disease (GERD) and urinary frequency are common underlying causes of frequent night waking.
- Pediatric restlessness and sleep difficulty — in the Müller-Klement 2006 study, the investigators dosed each child under 12 individually with a valerian-lemon balm combination; the study abstract gives no fixed dose per age or weight.
- Menopause-related sleep disturbance — lemon balm combinations with valerian are used, and Black Cohosh is used for vasomotor symptoms when hot flashes are the trigger.
- Tapering off chronic benzodiazepines or Z-drugs — herbal practitioners describe using a valerian-lemon balm combination while the prescription is tapered gradually. The zolpidem, zaleplon and eszopiclone labels warn that withdrawal symptoms may occur with rapid dose reduction or stopping.
- Combined with sleep hygiene — practitioners describe lemon balm as one part of a wider approach including consistent sleep timing, cool dark bedroom, no screens 60-90 minutes before bed, and limitation of evening caffeine and alcohol. See Sleep Hygiene.
Cautions and Drug Interactions
- Additive sedation with GABAergic drugs — combining lemon balm with benzodiazepines, Z-drugs, barbiturates, alcohol, opioids, gabapentin, pregabalin, or valproate can produce additive central nervous system depression. The magnitude is described as modest at typical doses; the concern is greatest for people on long-term sedating prescriptions.
- Thyroid function — theoretical thyroid-stimulating hormone-receptor binding by lemon balm extracts. The concern applies to long-term high-dose lemon balm alongside thyroid hormone replacement, where thyroid-stimulating hormone (TSH) levels are the measure that would show an effect.
- Pregnancy and lactation — not formally cleared. Tea-strength culinary use appears safe; there is no good safety data on high-dose extracts in pregnancy.
- Pre-operative — because of the additive sedation described above, the stop interval usually described for sedating herbs before surgery is 1-2 weeks.
- Pediatric use — in the Müller-Klement 2006 open study of 918 children, the investigators dosed each child individually and reported no study medication-related adverse events.
- Driving — at typical doses lemon balm does not impair driving. At evening sleep-onset doses (600-900 mg) the morning after, no significant residual effect on driving has been documented in trials, but individual response varies.
- Long-term safety — lemon balm has been used as a culinary and medicinal herb for over 2,000 years with an excellent safety record. There is no documented hepatotoxicity (LiverTox: no convincing reports of liver injury attributable to Melissa officinalis), no renal toxicity, no documented neurologic toxicity, no cancer signal.
Key Research Papers
- Cases J, Ibarra A, Feuillère N, Roller M, Sukkar SG (2011). Pilot trial of Melissa officinalis L. leaf extract in the treatment of volunteers suffering from mild-to-moderate anxiety disorders and sleep disturbances. Mediterranean Journal of Nutrition and Metabolism 2011;4(3):211-218. — PubMed PMID: 22207903
- Müller SF, Klement S (2006). A combination of valerian and lemon balm is effective in the treatment of restlessness and dyssomnia in children. Phytomedicine 2006;13(6):383-387. — PubMed PMID: 16487692
- Di Pierro F, Sisti D, Rocchi M, Belli A, Bertuccioli A, Cazzaniga M, Palazzi CM, Tanda ML, Zerbinati N (2024). Effects of Melissa officinalis Phytosome on Sleep Quality: Results of a Prospective, Double-Blind, Placebo-Controlled, and Cross-Over Study. Nutrients 2024;16(23):4199. — PubMed PMID: 39683592
- Ghazizadeh J, Sadigh-Eteghad S, Marx W, Fakhari A, Hamedeyazdan S, Torbati M, Taheri-Tarighi S, Araj-Khodaei M, Mirghafourvand M (2021). The effects of lemon balm (Melissa officinalis L.) on depression and anxiety in clinical trials: A systematic review and meta-analysis. Phytotherapy Research 2021;35(12):6690-6705. — PubMed PMID: 34449930
- Cerny A, Schmid K (1999). Tolerability and efficacy of valerian/lemon balm in healthy volunteers (a double-blind, placebo-controlled, multicentre study). Fitoterapia 1999;70(3):221-228. — doi:10.1016/S0367-326X(99)00018-0
- Schulz V, Hänsel R, Tyler VE (2001). Central Nervous System. In: Rational Phytotherapy: A Physicians' Guide to Herbal Medicine. Springer, Berlin, Heidelberg. — doi:10.1007/978-3-642-98093-0_2
- Kennedy DO, Little W, Haskell CF, Scholey AB (2006). Anxiolytic effects of a combination of Melissa officinalis and Valeriana officinalis during laboratory induced stress. Phytotherapy Research 2006;20(2):96-102. — PubMed PMID: 16444660
- Awad R, Levac D, Cybulska P, Merali Z, Trudeau VL, Arnason JT (2007). Effects of traditionally used anxiolytic botanicals on enzymes of the gamma-aminobutyric acid (GABA) system. Canadian Journal of Physiology and Pharmacology 2007;85(9):933-942. — PubMed PMID: 18066140
- Khom S, Baburin I, Timin E, Hohaus A, Trauner G, Kopp B, Hering S (2007). Valerenic acid potentiates and inhibits GABA-A receptors: molecular mechanism and subunit specificity. Neuropharmacology 2007;53(1):178-187. — PubMed PMID: 17585957
- Bent S, Padula A, Moore D, Patterson M, Mehling W (2006). Valerian for sleep: a systematic review and meta-analysis. American Journal of Medicine 2006;119(12):1005-1012. — PubMed PMID: 17145239
- Taibi DM, Landis CA, Petry H, Vitiello MV (2007). A systematic review of valerian as a sleep aid: safe but not effective. Sleep Medicine Reviews 2007;11(3):209-230. — PubMed PMID: 17517355
- Wheatley D (2005). Medicinal plants for insomnia: a review of their pharmacology, efficacy and tolerability. Journal of Psychopharmacology 2005;19(4):414-421. — PubMed PMID: 15982998
- Sarris J, Byrne GJ (2011). A systematic review of insomnia and complementary medicine. Sleep Medicine Reviews 2011;15(2):99-106. — PubMed PMID: 20965131
- Shakeri A, Sahebkar A, Javadi B (2016). Melissa officinalis L. - A review of its traditional uses, phytochemistry and pharmacology. Journal of Ethnopharmacology 2016;188:204-228. — PubMed PMID: 27167460
- Erland LA, Saxena PK (2017). Melatonin Natural Health Products and Supplements: Presence of Serotonin and Significant Variability of Melatonin Content. Journal of Clinical Sleep Medicine 2017;13(2):275-281. — PubMed PMID: 27855744